SK286282B6 - Deriváty 6-merkaptocyklodextrínu, farmaceutický prostriedok s ich obsahom, súprava s ich obsahom a ich použitie - Google Patents
Deriváty 6-merkaptocyklodextrínu, farmaceutický prostriedok s ich obsahom, súprava s ich obsahom a ich použitie Download PDFInfo
- Publication number
- SK286282B6 SK286282B6 SK726-2002A SK7262002A SK286282B6 SK 286282 B6 SK286282 B6 SK 286282B6 SK 7262002 A SK7262002 A SK 7262002A SK 286282 B6 SK286282 B6 SK 286282B6
- Authority
- SK
- Slovakia
- Prior art keywords
- per
- cyclodextrin
- deoxy
- thio
- mercaptocyclodextrin
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 6
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 98
- -1 carboxyphenyl Chemical group 0.000 claims abstract description 72
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- 239000000842 neuromuscular blocking agent Substances 0.000 claims abstract description 19
- 206010029315 Neuromuscular blockade Diseases 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 12
- 229940079593 drug Drugs 0.000 claims abstract description 8
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 6
- YXRDKMPIGHSVRX-OOJCLDBCSA-N rocuronium Chemical compound N1([C@@H]2[C@@H](O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(CC=C)CCCC2)CCOCC1 YXRDKMPIGHSVRX-OOJCLDBCSA-N 0.000 claims abstract description 6
- 229960000491 rocuronium Drugs 0.000 claims abstract description 6
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 claims abstract description 5
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims abstract description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims abstract 5
- 238000007911 parenteral administration Methods 0.000 claims abstract 2
- 239000001116 FEMA 4028 Substances 0.000 claims description 12
- 229960004853 betadex Drugs 0.000 claims description 12
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000002947 alkylene group Chemical group 0.000 claims description 4
- 229960005457 pancuronium Drugs 0.000 claims description 4
- GVEAYVLWDAFXET-XGHATYIMSA-N pancuronium Chemical compound C[N+]1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 GVEAYVLWDAFXET-XGHATYIMSA-N 0.000 claims description 4
- LVQTUXZKLGXYIU-GWSNJHLMSA-M rapacuronium Chemical compound [Br-].N1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)CC)[N+]2(CC=C)CCCCC2)CCCCC1 LVQTUXZKLGXYIU-GWSNJHLMSA-M 0.000 claims description 4
- 229960004804 rapacuronium Drugs 0.000 claims description 4
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 4
- BGSZAXLLHYERSY-XQIGCQGXSA-N vecuronium Chemical compound N1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 BGSZAXLLHYERSY-XQIGCQGXSA-N 0.000 claims description 4
- 229960003819 vecuronium Drugs 0.000 claims description 4
- JFJZZMVDLULRGK-URLMMPGGSA-O tubocurarine Chemical compound C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CCN3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 JFJZZMVDLULRGK-URLMMPGGSA-O 0.000 claims description 3
- 229960001844 tubocurarine Drugs 0.000 claims description 3
- WMSYWJSZGVOIJW-ONUALHDOSA-L Mivacurium chloride Chemical compound [Cl-].[Cl-].C([C@@H]1C2=CC(OC)=C(OC)C=C2CC[N+]1(C)CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]1(CCC=2C=C(C(=CC=2[C@H]1CC=1C=C(OC)C(OC)=C(OC)C=1)OC)OC)C)C1=CC(OC)=C(OC)C(OC)=C1 WMSYWJSZGVOIJW-ONUALHDOSA-L 0.000 claims description 2
- 229960002540 mivacurium Drugs 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229940120904 succinylcholine chloride Drugs 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- YOEWQQVKRJEPAE-UHFFFAOYSA-L succinylcholine chloride (anhydrous) Chemical compound [Cl-].[Cl-].C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C YOEWQQVKRJEPAE-UHFFFAOYSA-L 0.000 claims 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 61
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 50
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 47
- 239000000203 mixture Substances 0.000 description 37
- 239000000243 solution Substances 0.000 description 33
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 32
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 29
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 239000007787 solid Substances 0.000 description 27
- 150000001875 compounds Chemical class 0.000 description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 20
- 238000005481 NMR spectroscopy Methods 0.000 description 18
- 239000002244 precipitate Substances 0.000 description 17
- 238000001914 filtration Methods 0.000 description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 159000000000 sodium salts Chemical class 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 230000002441 reversible effect Effects 0.000 description 12
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 11
- 229960004373 acetylcholine Drugs 0.000 description 11
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 239000012312 sodium hydride Substances 0.000 description 10
- 229910000104 sodium hydride Inorganic materials 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 239000012299 nitrogen atmosphere Substances 0.000 description 8
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 7
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 7
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 7
- 229910000024 caesium carbonate Inorganic materials 0.000 description 7
- 230000002999 depolarising effect Effects 0.000 description 7
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- SJLBIPLIGYWGJV-UHFFFAOYSA-N N-nitroso-N-methyl-4-aminobutyric acid Chemical compound O=NN(C)CCCC(O)=O SJLBIPLIGYWGJV-UHFFFAOYSA-N 0.000 description 6
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 6
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 6
- 239000002738 chelating agent Substances 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 238000001819 mass spectrum Methods 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- AXOIZCJOOAYSMI-UHFFFAOYSA-N succinylcholine Chemical compound C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C AXOIZCJOOAYSMI-UHFFFAOYSA-N 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- 229940124596 AChE inhibitor Drugs 0.000 description 3
- 102100033639 Acetylcholinesterase Human genes 0.000 description 3
- 108010022752 Acetylcholinesterase Proteins 0.000 description 3
- YXSLJKQTIDHPOT-UHFFFAOYSA-N Atracurium Dibesylate Chemical compound C1=C(OC)C(OC)=CC=C1CC1[N+](CCC(=O)OCCCCCOC(=O)CC[N+]2(C)C(C3=CC(OC)=C(OC)C=C3CC2)CC=2C=C(OC)C(OC)=CC=2)(C)CCC2=CC(OC)=C(OC)C=C21 YXSLJKQTIDHPOT-UHFFFAOYSA-N 0.000 description 3
- 229930003347 Atropine Natural products 0.000 description 3
- 101100112679 Caenorhabditis elegans cyd-1 gene Proteins 0.000 description 3
- 244000025254 Cannabis sativa Species 0.000 description 3
- 101100169267 Escherichia coli (strain K12) cydA gene Proteins 0.000 description 3
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 229940022698 acetylcholinesterase Drugs 0.000 description 3
- 229960001862 atracurium Drugs 0.000 description 3
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 3
- 229960000396 atropine Drugs 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000003551 muscarinic effect Effects 0.000 description 3
- 239000003158 myorelaxant agent Substances 0.000 description 3
- 230000002232 neuromuscular Effects 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 229940032712 succinylcholine Drugs 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 2
- LMJXSOYPAOSIPZ-UHFFFAOYSA-N 4-sulfanylbenzoic acid Chemical compound OC(=O)C1=CC=C(S)C=C1 LMJXSOYPAOSIPZ-UHFFFAOYSA-N 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 206010008674 Cholinergic syndrome Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000002547 anomalous effect Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000028161 membrane depolarization Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004118 muscle contraction Effects 0.000 description 2
- 230000004220 muscle function Effects 0.000 description 2
- 229940035363 muscle relaxants Drugs 0.000 description 2
- 210000000715 neuromuscular junction Anatomy 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- CUJPFPXNDSIBPG-UHFFFAOYSA-N 1,3-propanediyl Chemical group [CH2]C[CH2] CUJPFPXNDSIBPG-UHFFFAOYSA-N 0.000 description 1
- OMIVCRYZSXDGAB-UHFFFAOYSA-N 1,4-butanediyl Chemical group [CH2]CC[CH2] OMIVCRYZSXDGAB-UHFFFAOYSA-N 0.000 description 1
- CAULSPKRQNHKIT-UHFFFAOYSA-N 2-(2-sulfanylethoxy)ethanol Chemical compound OCCOCCS CAULSPKRQNHKIT-UHFFFAOYSA-N 0.000 description 1
- ORXSLDYRYTVAPC-UHFFFAOYSA-N 2-(4-sulfanylphenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(S)C=C1 ORXSLDYRYTVAPC-UHFFFAOYSA-N 0.000 description 1
- MMHHBAUIJVTLFZ-UHFFFAOYSA-N 2-(bromomethyl)-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)CBr MMHHBAUIJVTLFZ-UHFFFAOYSA-N 0.000 description 1
- DKIDEFUBRARXTE-UHFFFAOYSA-N 3-mercaptopropanoic acid Chemical compound OC(=O)CCS DKIDEFUBRARXTE-UHFFFAOYSA-N 0.000 description 1
- RSFDFESMVAIVKO-UHFFFAOYSA-N 3-sulfanylbenzoic acid Chemical compound OC(=O)C1=CC=CC(S)=C1 RSFDFESMVAIVKO-UHFFFAOYSA-N 0.000 description 1
- CQPGDDAKTTWVDD-UHFFFAOYSA-N 4-bromobutanenitrile Chemical compound BrCCCC#N CQPGDDAKTTWVDD-UHFFFAOYSA-N 0.000 description 1
- DTRIDVOOPAQEEL-UHFFFAOYSA-N 4-sulfanylbutanoic acid Chemical compound OC(=O)CCCS DTRIDVOOPAQEEL-UHFFFAOYSA-N 0.000 description 1
- CMNQZZPAVNBESS-UHFFFAOYSA-N 6-sulfanylhexanoic acid Chemical compound OC(=O)CCCCCS CMNQZZPAVNBESS-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000032529 Accidental overdose Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 208000001308 Fasciculation Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- RVOLLAQWKVFTGE-UHFFFAOYSA-N Pyridostigmine Chemical compound CN(C)C(=O)OC1=CC=C[N+](C)=C1 RVOLLAQWKVFTGE-UHFFFAOYSA-N 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 101100073357 Streptomyces halstedii sch2 gene Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 150000001356 alkyl thiols Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical group OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 150000001504 aryl thiols Chemical class 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- VTJUKNSKBAOEHE-UHFFFAOYSA-N calixarene Chemical class COC(=O)COC1=C(CC=2C(=C(CC=3C(=C(C4)C=C(C=3)C(C)(C)C)OCC(=O)OC)C=C(C=2)C(C)(C)C)OCC(=O)OC)C=C(C(C)(C)C)C=C1CC1=C(OCC(=O)OC)C4=CC(C(C)(C)C)=C1 VTJUKNSKBAOEHE-UHFFFAOYSA-N 0.000 description 1
- 150000001723 carbon free-radicals Chemical class 0.000 description 1
- 230000011128 cardiac conduction Effects 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000003983 crown ethers Chemical class 0.000 description 1
- 239000012045 crude solution Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000002635 electroconvulsive therapy Methods 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- PVBRSNZAOAJRKO-UHFFFAOYSA-N ethyl 2-sulfanylacetate Chemical compound CCOC(=O)CS PVBRSNZAOAJRKO-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004868 gas analysis Methods 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000011597 hartley guinea pig Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- PXSVQMKXJZTWPN-UHFFFAOYSA-N methyl 2-methyl-3-sulfanylpropanoate Chemical compound COC(=O)C(C)CS PXSVQMKXJZTWPN-UHFFFAOYSA-N 0.000 description 1
- YRIAPEVGKLRGHX-UHFFFAOYSA-N methyl 4-sulfanylbutanoate Chemical compound COC(=O)CCCS YRIAPEVGKLRGHX-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- GGQQANJFYSLXPI-UHFFFAOYSA-N n-methylsulfanylacetamide Chemical compound CSNC(C)=O GGQQANJFYSLXPI-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-M naphthalene-1-sulfonate Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-M 0.000 description 1
- OPECTNGATDYLSS-UHFFFAOYSA-N naphthalene-2-sulfonyl chloride Chemical compound C1=CC=CC2=CC(S(=O)(=O)Cl)=CC=C21 OPECTNGATDYLSS-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229960002362 neostigmine Drugs 0.000 description 1
- LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 description 1
- 210000003758 neuroeffector junction Anatomy 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- 238000002616 plasmapheresis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229960002290 pyridostigmine Drugs 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229960003682 rocuronium bromide Drugs 0.000 description 1
- OYTJKRAYGYRUJK-FMCCZJBLSA-M rocuronium bromide Chemical compound [Br-].N1([C@@H]2[C@@H](O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(CC=C)CCCC2)CCOCC1 OYTJKRAYGYRUJK-FMCCZJBLSA-M 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- HNFOAHXBHLWKNF-UHFFFAOYSA-N sodium;2-bromoethanesulfonic acid Chemical compound [Na+].OS(=O)(=O)CCBr HNFOAHXBHLWKNF-UHFFFAOYSA-N 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- NBOMNTLFRHMDEZ-UHFFFAOYSA-N thiosalicylic acid Chemical compound OC(=O)C1=CC=CC=C1S NBOMNTLFRHMDEZ-UHFFFAOYSA-N 0.000 description 1
- 229940103494 thiosalicylic acid Drugs 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 229950004288 tosilate Drugs 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99309558 | 1999-11-29 | ||
| PCT/EP2000/011789 WO2001040316A1 (en) | 1999-11-29 | 2000-11-23 | 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK7262002A3 SK7262002A3 (en) | 2002-11-06 |
| SK286282B6 true SK286282B6 (sk) | 2008-06-06 |
Family
ID=8241767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK726-2002A SK286282B6 (sk) | 1999-11-29 | 2000-11-23 | Deriváty 6-merkaptocyklodextrínu, farmaceutický prostriedok s ich obsahom, súprava s ich obsahom a ich použitie |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | USRE44733E1 (sr) |
| EP (1) | EP1259550B1 (sr) |
| JP (2) | JP3880041B2 (sr) |
| KR (1) | KR100716524B1 (sr) |
| CN (1) | CN1188428C (sr) |
| AR (1) | AR026605A1 (sr) |
| AT (1) | ATE288450T1 (sr) |
| AU (1) | AU776536B2 (sr) |
| BE (1) | BE2008C047I2 (sr) |
| BR (1) | BRPI0015947B8 (sr) |
| CA (1) | CA2390463C (sr) |
| CO (1) | CO5251450A1 (sr) |
| CY (1) | CY2008018I1 (sr) |
| CZ (1) | CZ298206B6 (sr) |
| DE (2) | DE60017947T2 (sr) |
| DK (1) | DK1259550T3 (sr) |
| ES (1) | ES2237496T3 (sr) |
| FR (1) | FR08C0052I2 (sr) |
| HK (1) | HK1049489A1 (sr) |
| HU (1) | HU227451B1 (sr) |
| IL (1) | IL149423A0 (sr) |
| LU (1) | LU91501I2 (sr) |
| MX (1) | MXPA02004940A (sr) |
| NL (1) | NL300356I2 (sr) |
| NO (2) | NO328790B1 (sr) |
| NZ (1) | NZ518752A (sr) |
| PE (1) | PE20010902A1 (sr) |
| PL (1) | PL203012B1 (sr) |
| PT (1) | PT1259550E (sr) |
| RU (1) | RU2260013C2 (sr) |
| SK (1) | SK286282B6 (sr) |
| TW (1) | TWI242015B (sr) |
| WO (1) | WO2001040316A1 (sr) |
| ZA (1) | ZA200203538B (sr) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6744471B1 (en) * | 1997-12-05 | 2004-06-01 | Olympus Optical Co., Ltd | Electronic camera that synthesizes two images taken under different exposures |
| TWI242015B (en) | 1999-11-29 | 2005-10-21 | Akzo Nobel Nv | 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block |
| WO2002036105A2 (en) * | 2000-11-02 | 2002-05-10 | Akzo Nobel N.V. | Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders |
| AU2004285032A1 (en) | 2003-10-31 | 2005-05-12 | The University Of Kansas | Sulfoalkyl ether-alkyl ether cyclodextrin derivatives |
| US7851457B2 (en) | 2004-01-29 | 2010-12-14 | Innovative Biologics, Inc. | β-Cyclodextrin derivatives |
| RU2006141358A (ru) | 2004-04-23 | 2008-05-27 | Сайдекс, Инк. (Us) | Препаративная форма для ингалятора сухого порошка, содержащая простой сульфоалкиловый эфир циклодекстрина |
| RU2007133709A (ru) | 2005-01-28 | 2009-03-20 | Пиннекл Фармасьютиклз, Инк. (Us) | Производные в-циклодекстрина в качестве антибактериальных агентов |
| DK2581078T3 (en) | 2005-10-26 | 2015-03-02 | Cydex Pharmaceuticals Inc | Sulfoalkylætercyclodekstrinsammensætninger and processes for the preparation thereof |
| US7629331B2 (en) | 2005-10-26 | 2009-12-08 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
| US20090069412A1 (en) * | 2007-09-09 | 2009-03-12 | Protia, Llc | Deuterium-enriched sugammadex |
| US7635773B2 (en) | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
| US7938283B2 (en) * | 2008-06-20 | 2011-05-10 | Grainpro, Inc. | System and method for hermetic storage of agricultural commodities during shipping |
| US10463677B2 (en) | 2008-11-07 | 2019-11-05 | Cydex Pharmaceuticals, Inc. | Composition containing sulfoalkyl ether cyclodextrin and latanoprost |
| CN101591402B (zh) * | 2009-05-05 | 2011-11-30 | 杭州奥默医药技术有限公司 | 6-脱氧砜类环糊精衍生物及其制备方法 |
| US8492538B1 (en) | 2009-06-04 | 2013-07-23 | Jose R. Matos | Cyclodextrin derivative salts |
| DE102010012281A1 (de) * | 2010-03-22 | 2011-09-22 | Fresenius Medical Care Deutschland Gmbh | Pharmazeutische Zusammensetzungen enthaltend substituiertes 6-Deoxy-6-sulfanylcyclodextrin |
| CN101864003B (zh) * | 2010-06-11 | 2012-05-02 | 漆又毛 | 一种6-脱氧硫醚氨基酸环糊精衍生物的合成方法 |
| WO2012025937A1 (en) | 2010-08-25 | 2012-03-01 | Ramamohan Rao Davuluri | Improved process for preparation of sugammadex |
| CN102060941B (zh) * | 2010-11-26 | 2012-12-26 | 漆又毛 | 6-脱氧α-氨基酸衍生物环糊精及制备和应用 |
| DK3702374T3 (da) | 2012-02-15 | 2022-06-27 | Cydex Pharmaceuticals Inc | Fremsgangsmåde til fremstilling for cyclodextrin-derivater |
| KR20200106100A (ko) | 2012-02-28 | 2020-09-10 | 사이덱스 파마슈티칼스, 인크. | 알킬화된 시클로덱스트린 조성물 및 이의 제조 및 사용 방법 |
| JP5892847B2 (ja) * | 2012-04-27 | 2016-03-23 | Ｄｏｗａホールディングス株式会社 | シクロデキストリンとシリカ含有物質との複合材料、及びその製造方法、並びにガス吸着剤 |
| GB201211153D0 (en) * | 2012-06-22 | 2012-08-08 | Farmhispania | Pharmaceutical compositions |
| CA2888822C (en) | 2012-10-22 | 2021-01-26 | Cydex Pharmaceuticals, Inc. | Alkylated cyclodextrin compositions and processes for preparing and using the same |
| EP2956486B1 (en) * | 2013-02-14 | 2020-09-30 | Neuland Laboratories Ltd | An improved process for preparation of sugammadex sodium |
| EP3149052A4 (en) | 2014-05-29 | 2018-01-03 | UTI Limited Partnership | Cyclodextrin-based polyanionic and non-ionic dendrimers |
| WO2015198456A1 (ja) | 2014-06-26 | 2015-12-30 | 丸石製薬株式会社 | 安定性を改善したロクロニウム製剤 |
| WO2016029179A1 (en) | 2014-08-22 | 2016-02-25 | Cydex Pharmaceuticals, Inc. | Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same |
| CN105348412B (zh) * | 2014-08-22 | 2018-06-05 | 江苏恩华药业股份有限公司 | 一种舒更葡糖钠的纯化方法 |
| CN108348560A (zh) | 2015-03-19 | 2018-07-31 | 锡德克斯药物公司 | 包含水飞蓟素和磺烃基醚环糊精的组合物及其使用方法 |
| CN104844732B (zh) * | 2015-03-27 | 2017-05-03 | 山东滨州智源生物科技有限公司 | 一种舒更葡糖钠的制备方法 |
| US20180296679A1 (en) * | 2015-04-08 | 2018-10-18 | Chang-Chun Ling | Pharmaceutical compositions of polyanionic and non-ionic cyclodextrin-based dendrimers and uses thereof |
| US10494450B2 (en) * | 2015-05-29 | 2019-12-03 | Lakshmi Prasad ALAPARTHI | Processes for preparation of Sugammadex and intermediates thereof |
| CN104922693A (zh) * | 2015-06-19 | 2015-09-23 | 南开大学 | 一种阴离子型环糊精与抗癌药物包合物及制备方法 |
| CA3001200A1 (en) * | 2015-10-07 | 2017-04-13 | Uti Limited Partnership | Multifunctional polyanionic cyclodextrin dendrimers |
| WO2017089966A1 (en) | 2015-11-25 | 2017-06-01 | Fresenius Kabi Antiinfectives S.R.L. | An improved process for the preparation of sugammadex and its intermediates |
| US10414830B2 (en) | 2015-11-25 | 2019-09-17 | Fresenius Kabi Ipsum S.R.L. | Crystalline forms of per-chloro-γ-cyclodextrines |
| ES2810980T3 (es) | 2016-03-22 | 2021-03-10 | Fresenius Kabi Ipsum S R L | Un proceso mejorado para la preparación de sugammadex |
| CN109414452B (zh) * | 2016-04-29 | 2024-02-02 | 阿弗隆制药有限公司 | 作为促凝血剂的环糊精 |
| ES2915423T3 (es) | 2016-06-23 | 2022-06-22 | Synthon Bv | Proceso de preparación de sugammadex |
| JP6692941B2 (ja) * | 2016-06-29 | 2020-05-27 | 北京叡創康泰医薬研究院有限公司Ｂｅｉｊｉｎｇ Ｃｒｅａｔｒｏｎ Ｉｎｓｔｉｔｕｔｅ ｏｆ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｒｅｓｅａｒｃｈ Ｃｏ．， Ｌｔｄ． | スガマデックスの製造及び純化方法 |
| US10526422B2 (en) | 2016-06-29 | 2020-01-07 | Beijing Creatron Institute Of Pharmaceutical Research Co., Ltd. | Process for preparation and purification of Sugammades sodium |
| CN107778383B (zh) * | 2016-08-24 | 2020-03-10 | 王炳永 | 一种舒更葡糖钠的精制方法 |
| US10385142B2 (en) | 2017-01-23 | 2019-08-20 | Scinopharm Taiwan, Ltd. | Method for preparing sugammadex sodium |
| AU2018263924B2 (en) | 2017-05-03 | 2024-07-04 | Cydex Pharmaceuticals, Inc. | Composition containing cyclodextrin and busulfan |
| CN109021148B (zh) * | 2017-06-08 | 2020-11-10 | 天津科伦药物研究有限公司 | 一种制备舒更葡糖钠的方法 |
| US10442871B2 (en) | 2017-06-22 | 2019-10-15 | Lawrence Livermore National Security, Llc | Modified cyclodextrins for the selective sequestration of fentanyl related compounds and uses thereof |
| ES2761899T3 (es) | 2017-06-30 | 2020-05-21 | Synthon Bv | Proceso para preparar Sugammadex |
| US10233263B1 (en) * | 2017-08-23 | 2019-03-19 | Formosa Laboratories, Inc. | Method for preparation of sugammadex sodium |
| TWI703163B (zh) * | 2017-08-23 | 2020-09-01 | 台耀化學股份有限公司 | 舒更葡糖鈉之製備方法及其晶型 |
| CN107892727B (zh) * | 2017-11-27 | 2019-12-24 | 合肥博思科创医药科技有限公司 | 一种舒更葡糖钠的纯化方法 |
| ES2948930T3 (es) | 2017-11-27 | 2023-09-21 | Medichem Sa | Proceso para la síntesis de un derivado de ciclodextrina |
| EP3775026B1 (en) | 2018-04-06 | 2022-03-16 | Synthon B.V. | Purification of sugammadex |
| KR102054228B1 (ko) * | 2018-05-28 | 2019-12-10 | 연성정밀화학(주) | 슈가마덱스 나트륨염의 제조방법 |
| BR112020024822B1 (pt) | 2018-06-07 | 2024-03-12 | Merck Sharp & Dohme Llc | Processos para a preparação de sugammadex |
| CN110615860A (zh) * | 2018-06-20 | 2019-12-27 | 江苏恒瑞医药股份有限公司 | 一种舒更葡糖钠的纯化方法 |
| EP3830184A1 (en) | 2018-08-02 | 2021-06-09 | Pliva Hrvatska D.O.O. | Solid state forms of sugammadex sodium |
| US11845811B2 (en) * | 2018-09-20 | 2023-12-19 | Natco Pharma Limited | Process for the preparation of Sugammadex sodium and its novel polymorphic form |
| CN112752770A (zh) | 2018-09-27 | 2021-05-04 | 韦尔滕施泰因生物制药公司 | 舒更葡糖的新型晶体形式 |
| JP6950966B2 (ja) * | 2018-11-01 | 2021-10-13 | 丸石製薬株式会社 | スガマデクス又はその薬理学的に許容される塩含有液剤及びその製造方法 |
| CN109438591B (zh) * | 2018-12-29 | 2021-02-09 | 博瑞生物医药（苏州）股份有限公司 | 舒更葡糖钠的制备工艺 |
| CN109824800A (zh) * | 2018-12-29 | 2019-05-31 | 鼎元(天津)生物医药科技有限公司 | 一种选择性肌松拮抗药舒更葡萄糖钠的制备方法 |
| WO2020201930A1 (en) | 2019-03-29 | 2020-10-08 | Hospira, Inc. | An improved process for preparation of sugammadex acid and sugammadex sodium |
| CN111978435B (zh) | 2019-05-22 | 2021-05-25 | 合肥博思科创医药科技有限公司 | 一种高纯度舒更葡糖钠的制备方法 |
| US11324692B2 (en) | 2019-07-03 | 2022-05-10 | Galenicum Health S.L.U. | Method to prepare pharmaceutical compositions of suggamadex |
| EP4023292A4 (en) | 2019-08-30 | 2023-09-06 | TERUMO Kabushiki Kaisha | INJECTION FORMULATION |
| RU2724900C1 (ru) * | 2019-10-24 | 2020-06-26 | Маруиси Фармасьютикал Ко., Лтд. | Препарат рокурония с улучшенной стабильностью |
| CN111019016B (zh) * | 2019-12-27 | 2022-02-18 | 武汉嘉诺康医药技术有限公司 | 一种舒更葡糖钠杂质的合成方法 |
| JP2023515087A (ja) | 2020-02-28 | 2023-04-12 | メディチェム エセ．ア． | スガマデクスを乾燥させるための方法 |
| CN111714459B (zh) * | 2020-06-18 | 2022-06-14 | 广州瑞尔医药科技有限公司 | 一种注射用舒更葡糖钠粉针剂及其制备方法 |
| US11097023B1 (en) | 2020-07-02 | 2021-08-24 | Par Pharmaceutical, Inc. | Pre-filled syringe containing sugammadex |
| ES2949710T1 (es) | 2020-07-03 | 2023-10-02 | Galenicum Health S L U | Método para preparar composiciones farmacéuticas |
| US11446325B2 (en) * | 2020-09-30 | 2022-09-20 | Cyclolab Cyclodextrin Research And Development Laboratory Ltd. | Cyclodextrin derivatives in the treatment or prevention of lysosomal neurodegenerative diseases |
| US11945788B2 (en) | 2021-06-07 | 2024-04-02 | Nuray Chemicals Private Limited | Process for preparing pitolisant hydrochloride and solid-state forms thereof |
| CN113637097A (zh) * | 2021-08-10 | 2021-11-12 | 北京恒创星远医药科技有限公司 | 6-全脱氧-6-全碘代-γ-环糊精晶体及其制备方法和应用 |
| CN115708777A (zh) | 2021-08-19 | 2023-02-24 | 北京费森尤斯卡比医药有限公司 | 包含巯基环糊精衍生物或其可药用盐的包装药品和保存方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3929813A (en) | 1973-12-26 | 1975-12-30 | Interx Research Corp | Novel pro-drug derivatives of pyridinium aldoxime type cholinesterase reactivators and process for preparing same |
| JPS52108027A (en) | 1976-03-09 | 1977-09-10 | Rikagaku Kenkyusho | Anticarcinogen |
| US4816462A (en) | 1982-05-18 | 1989-03-28 | Nowicky Wassili | Method for diagnosing and for the therapeutic treatment of tumors and/or infectious diseases of different types with alkaloid-compounds |
| HU194858B (en) | 1982-12-03 | 1988-03-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing dibenzo/b,d/pirane derivatives and pharmaceutical compositions containing them |
| IT1196033B (it) | 1984-02-22 | 1988-11-10 | Chiesi Farma Spa | Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche |
| US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| GB8506792D0 (en) | 1985-03-15 | 1985-04-17 | Janssen Pharmaceutica Nv | Derivatives of y-cyclodextrin |
| GB8613688D0 (en) | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| JPH0819004B2 (ja) | 1986-12-26 | 1996-02-28 | 日清製粉株式会社 | 徐放性医薬製剤 |
| HU201783B (en) | 1987-10-13 | 1990-12-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing partially methylized carboxy-acyl-beta-cyclodextrines and salts |
| US5017566A (en) | 1987-12-30 | 1991-05-21 | University Of Florida | Redox systems for brain-targeted drug delivery |
| US5002935A (en) | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
| DE69032370T2 (de) | 1989-04-03 | 1998-10-29 | Janssen Pharmaceutica N.V., Beerse | Regioselektive substitutionen von cyclodextrinen |
| US5173481A (en) | 1989-04-03 | 1992-12-22 | The United States Of America As Represented By The Department Of Health And Human Services | Preparation of specifically substituted cyclodextrins |
| ES2067854T3 (es) * | 1990-03-15 | 1995-04-01 | Tanabe Seiyaku Co | Polisulfato de derivado de ciclodextrina y procedimiento para preparar el mismo. |
| US5180716A (en) * | 1990-08-01 | 1993-01-19 | The Regents Of The University Of California | Cyclodextrin complexes for neuraxial administration of drugs |
| JP2556236B2 (ja) | 1991-08-29 | 1996-11-20 | 田辺製薬株式会社 | β−シクロデキストリン誘導体のポリ硫酸エステル及びその製法 |
| US5840881A (en) | 1992-11-27 | 1998-11-24 | Takeda Chemical Industries, Ltd. | Composition containing a water-insoluble or slightly water-soluble compound with enhanced water-solubility |
| US5767112A (en) | 1994-10-21 | 1998-06-16 | Poli Industria Chimica, S.P.A. | Muscle relaxant pharmaceutical compositions |
| AU708107B2 (en) | 1994-11-04 | 1999-07-29 | Commonwealth Scientific And Industrial Research Organisation | Method for treating animals |
| GB2307176A (en) * | 1995-11-15 | 1997-05-21 | Todd Selwyn Everest | Anti-inflammatory clathrating agents for topical use |
| US5935941A (en) | 1997-10-24 | 1999-08-10 | Pitha; Josef | Alkylations of cyclodextrins leading to derivatives which have a ridgidly extended cavity |
| US5834446A (en) * | 1996-06-21 | 1998-11-10 | Queen's University At Kingston | Nerve process growth modulators |
| JP4249282B2 (ja) | 1998-02-27 | 2009-04-02 | 日本食品化工株式会社 | 新規シクロデキストリン誘導体及びその製造方法 |
| JP4817495B2 (ja) | 1998-05-29 | 2011-11-16 | ニューロサイエンシーズ・リサーチ・ファウンデーション・インコーポレーテッド | 外因性カンナビノイドでの痛みの制御 |
| MXPA02001545A (es) * | 1999-08-13 | 2002-08-30 | Akzo Nobel Nv | Uso de queladores quimicos como agentes de reversion para el bloqueo neuromuscular inducido por farmaco. |
| TWI242015B (en) | 1999-11-29 | 2005-10-21 | Akzo Nobel Nv | 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block |
| US20020111377A1 (en) | 2000-12-22 | 2002-08-15 | Albany College Of Pharmacy | Transdermal delivery of cannabinoids |
| WO2002064635A1 (en) | 2001-02-14 | 2002-08-22 | Akzo Nobel N.V. | 2-alkylated-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block |
| TW200402417A (en) | 2002-06-21 | 2004-02-16 | Akzo Nobel Nv | 1-[(Indol-3-yl)carbonyl]piperazine derivatives |
-
2000
- 2000-11-08 TW TW089123585A patent/TWI242015B/zh active
- 2000-11-23 US US13/432,742 patent/USRE44733E1/en active Active
- 2000-11-23 BR BRPI0015947 patent/BRPI0015947B8/pt not_active IP Right Cessation
- 2000-11-23 PT PT00993261T patent/PT1259550E/pt unknown
- 2000-11-23 DE DE60017947T patent/DE60017947T2/de not_active Expired - Lifetime
- 2000-11-23 JP JP2001541070A patent/JP3880041B2/ja not_active Expired - Lifetime
- 2000-11-23 DK DK00993261T patent/DK1259550T3/da active
- 2000-11-23 EP EP00993261A patent/EP1259550B1/en not_active Expired - Lifetime
- 2000-11-23 MX MXPA02004940A patent/MXPA02004940A/es active IP Right Grant
- 2000-11-23 ES ES00993261T patent/ES2237496T3/es not_active Expired - Lifetime
- 2000-11-23 KR KR1020027006871A patent/KR100716524B1/ko active IP Right Review Request
- 2000-11-23 NZ NZ518752A patent/NZ518752A/xx not_active IP Right Cessation
- 2000-11-23 DE DE122008000068C patent/DE122008000068I2/de active Active
- 2000-11-23 AU AU54380/01A patent/AU776536B2/en not_active Expired
- 2000-11-23 WO PCT/EP2000/011789 patent/WO2001040316A1/en active IP Right Grant
- 2000-11-23 CN CNB00816360XA patent/CN1188428C/zh not_active Expired - Lifetime
- 2000-11-23 AT AT00993261T patent/ATE288450T1/de active
- 2000-11-23 PL PL356097A patent/PL203012B1/pl unknown
- 2000-11-23 CA CA002390463A patent/CA2390463C/en not_active Expired - Lifetime
- 2000-11-23 CZ CZ20021814A patent/CZ298206B6/cs not_active IP Right Cessation
- 2000-11-23 HU HU0203755A patent/HU227451B1/hu active Protection Beyond IP Right Term
- 2000-11-23 IL IL14942300A patent/IL149423A0/xx active Protection Beyond IP Right Term
- 2000-11-23 SK SK726-2002A patent/SK286282B6/sk not_active IP Right Cessation
- 2000-11-23 US US10/148,307 patent/US6670340B1/en not_active Ceased
- 2000-11-23 RU RU2002117302/04A patent/RU2260013C2/ru active Protection Beyond IP Right Term
- 2000-11-27 AR ARP000106216A patent/AR026605A1/es active IP Right Grant
- 2000-11-28 PE PE2000001269A patent/PE20010902A1/es not_active IP Right Cessation
- 2000-11-28 CO CO00090982A patent/CO5251450A1/es active IP Right Grant
-
2002
- 2002-05-03 ZA ZA200203538A patent/ZA200203538B/en unknown
- 2002-05-28 NO NO20022522A patent/NO328790B1/no not_active IP Right Cessation
-
2003
- 2003-03-05 HK HK03101625A patent/HK1049489A1/xx not_active IP Right Cessation
- 2003-06-23 US US10/603,355 patent/US6949527B2/en not_active Expired - Lifetime
-
2006
- 2006-07-18 JP JP2006195089A patent/JP4563972B2/ja not_active Expired - Lifetime
-
2008
- 2008-08-06 NL NL300356C patent/NL300356I2/nl unknown
- 2008-11-25 CY CY200800018C patent/CY2008018I1/el unknown
- 2008-11-26 LU LU91501C patent/LU91501I2/xx unknown
- 2008-12-10 BE BE2008C047C patent/BE2008C047I2/fr unknown
- 2008-12-30 FR FR08C0052C patent/FR08C0052I2/fr active Active
-
2010
- 2010-11-10 NO NO2010019C patent/NO2010019I2/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK286282B6 (sk) | Deriváty 6-merkaptocyklodextrínu, farmaceutický prostriedok s ich obsahom, súprava s ich obsahom a ich použitie | |
| JP4313041B2 (ja) | ２−アルキル化−シクロデキストリン誘導体：薬物性神経筋遮断に対する拮抗薬 | |
| US20100075938A1 (en) | Use of Chemical Chelators as Reversal Agents for Drug-Induced Neuromuscular Block | |
| DE69104877T2 (de) | Polysulfat eines Cyclodextrinderivates und Verfahren zu dessen Herstellung. | |
| HU226370B1 (en) | Carbohydrate derivatives with antithrombotic activity and pharmaceutical compositions contg. them | |
| KR20190141244A (ko) | 사이클로덱스트린 및 부설판을 함유하는 조성물 | |
| PT94219A (pt) | Processo para a preparacao de composicoes farmaceuticas contendo carbamazepina | |
| US20110212907A1 (en) | Hexadecasaccharides with antithrombotic activity, including a covalent bond and an amino chain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC4A | Assignment and transfer of rights |
Owner name: MSD OSS B.V., OSS, NL Free format text: FORMER OWNER: N.V. ORGANON, OSS, NL Effective date: 20120326 |
|
| SPCT | Transfer of rights of an spc |
Owner name: MSD OSS B.V., OSS, NL Free format text: PRODUCT NAME: SUGAMMADEX; REGISTRATION NO/DATE: EU/1/08//466/001-002 20080725; FORMER OWNER: N. V. ORGANON, OSS, NL Spc suppl protection certif: 5007-2008; DO 74 Filing date: 20081216 Extension date: 20230725 Effective date: 20120326 |
|
| PC4A | Assignment and transfer of rights |
Owner name: MERCK SHARP & DOHME B.V., BN HAARLEM, NL Free format text: FORMER OWNER: ORGANON BIOSCIENCES NEDERLAND B.V., AB OSS, NL Effective date: 20130729 Owner name: ORGANON BIOSCIENCES NEDERLAND B.V., AB OSS, NL Free format text: FORMER OWNER: MSD OSS B.V., OSS, NL Effective date: 20130729 |
|
| MK4A | Patent expired |
Expiry date: 20201123 |